- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
LeMaitre Vascular Divests General Surgery Product Lines
LeMaitre Vascular (Nasdaq:LMAT), announced today that it has divested its general surgery product lines to Symmetry Surgical, Inc. for $7.4 million. Included in the divestiture were the Reddick Cholangiogram Catheter and Reddick Saye-Screw, both used during laparoscopic cholecystectomy procedures. As part of the transaction, the parties entered into a two-year manufacturing transition services agreement. As …
LeMaitre Vascular (Nasdaq:LMAT), announced today that it has divested its general surgery product lines to Symmetry Surgical, Inc. for $7.4 million. Included in the divestiture were the Reddick Cholangiogram Catheter and Reddick Saye-Screw, both used during laparoscopic cholecystectomy procedures. As part of the transaction, the parties entered into a two-year manufacturing transition services agreement.
As quoted in the press release:
Dave Roberts, LeMaitre Vascular’s President, commented, “We are pleased to divest these general surgical product lines and to rationalize our portfolio. Following this transaction, all of LeMaitre’s remaining 14 product lines are now focused on the needs of our core customer, the vascular surgeon.”
“Symmetry Surgical is excited to add the Reddick® product lines to our comprehensive laparoscopic portfolio,” says Scott Kunkel, Chief Financial Officer, Symmetry Surgical. “We look forward to partnering with LeMaitre Vascular during this transition period to provide excellent service to our customers.” In 2017, LeMaitre’s general surgery product lines accounted for $3.3 million in revenue and $2.5 million in gross profit.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â